Tetracosactide

Jump to: navigation, search
Tetracosactide
Tetracosactide.png
Clinical data
AHFS/Drugs.comInternational Drug Names
MedlinePlusa605020
ATC code
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC136H210N40O31S
Molar mass2933.44 g/mol
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Tetracosactide

Articles

Most recent articles on Tetracosactide

Most cited articles on Tetracosactide

Review articles on Tetracosactide

Articles on Tetracosactide in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Tetracosactide

Images of Tetracosactide

Photos of Tetracosactide

Podcasts & MP3s on Tetracosactide

Videos on Tetracosactide

Evidence Based Medicine

Cochrane Collaboration on Tetracosactide

Bandolier on Tetracosactide

TRIP on Tetracosactide

Clinical Trials

Ongoing Trials on Tetracosactide at Clinical Trials.gov

Trial results on Tetracosactide

Clinical Trials on Tetracosactide at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Tetracosactide

NICE Guidance on Tetracosactide

NHS PRODIGY Guidance

FDA on Tetracosactide

CDC on Tetracosactide

Books

Books on Tetracosactide

News

Tetracosactide in the news

Be alerted to news on Tetracosactide

News trends on Tetracosactide

Commentary

Blogs on Tetracosactide

Definitions

Definitions of Tetracosactide

Patient Resources / Community

Patient resources on Tetracosactide

Discussion groups on Tetracosactide

Patient Handouts on Tetracosactide

Directions to Hospitals Treating Tetracosactide

Risk calculators and risk factors for Tetracosactide

Healthcare Provider Resources

Symptoms of Tetracosactide

Causes & Risk Factors for Tetracosactide

Diagnostic studies for Tetracosactide

Treatment of Tetracosactide

Continuing Medical Education (CME)

CME Programs on Tetracosactide

International

Tetracosactide en Espanol

Tetracosactide en Francais

Business

Tetracosactide in the Marketplace

Patents on Tetracosactide

Experimental / Informatics

List of terms related to Tetracosactide

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Tetracosactide (marketed under the brand name Synacthen) is a synthetic analogue consisting of the first 24 amino acids of the naturally occurring adrenocorticotrophic hormone (ACTH). It is known to be used as a doping agent to increase the secretion of glucocorticoids by adrenal glands.[1]

Pharmacology

In the normal situation, ACTH is released from the pituitary gland at the base of the brain. It acts on the adrenal glands to stimulate the production of steroid hormones (glucocorticoids). If the adrenal glands are healthy, a single injection of tetracosactide results in a rise in blood cortisol (hydrocortisone) concentrations in 30 minutes. If the adrenal glands appear not to be working then tetracosactide injection can be given to check whether the problem is due to diseased or damaged adrenals or due to lack of pituitary ACTH.

Uses

This medication is used for diagnostic purposes only (e.g. in short synacthen test). It is suitable for treatment of adrenal insufficiency of central origin.

As well as its legitimate medical applications, it has been widely reported that Synacthen has also been used as an illegal performance enhancing drug by professional cyclists.[2]

It has been used in the treatment of infantile spasms.[3]

See also


References

  1. Chaabo A, de Ceaurriz J, Buisson C, Tabet JC, Lasne F (February 2011). "Simultaneous quantification and qualification of synacthen in plasma". Anal Bioanal Chem. 399 (5): 1835–43. doi:10.1007/s00216-010-4565-z. PMID 21170520.
  2. Kimmage P (2007). "tour 87 stage 14". Rough Ride. Yellow Jersey Press. p. 125. ISBN 0-224-08017-2.
  3. Lux AL, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Newton RW, O'Callaghan FJ, Verity CM, Osborne JP (2004). "The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial". Lancet. 364 (9447): 1773–8. doi:10.1016/S0140-6736(04)17400-X. PMID 15541450.

Linked-in.jpg